L7045
L 748337 hydrate
≥98% (HPLC)
别名:
N-(3-{3-[2-(4-Benzenesulfonylamino-phenyl)-ethylamino]-(2S)-2-hydroxy-propoxy}-benzyl)-acetamide hydrate; Acetamide, N-[[3-[(2S)-2-hydroxy-3-[[2-[4-[(phenylsulfonyl)amino]phenyl]ethyl]amino]propoxy]phenyl]methyl] hydrate
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C26H31N3O5S · xH2O
分子量:
497.61 (anhydrous basis)
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D +4.0 to +8.0°, c = 4 in DMSO
solubility
DMSO: >12 mg/mL
originator
Merck & Co., Inc., Kenilworth, NJ, U.S.
storage temp.
2-8°C
SMILES string
O.CC(=O)NCc1cccc(OC[C@@H](O)CNCCc2ccc(NS(=O)(=O)c3ccccc3)cc2)c1
InChI
1S/C26H31N3O5S.H2O/c1-20(30)28-17-22-6-5-7-25(16-22)34-19-24(31)18-27-15-14-21-10-12-23(13-11-21)29-35(32,33)26-8-3-2-4-9-26;/h2-13,16,24,27,29,31H,14-15,17-19H2,1H3,(H,28,30);1H2/t24-;/m0./s1
InChI key
TYFJHLUOBDKUID-JIDHJSLPSA-N
Biochem/physiol Actions
L 748337 is a β3 adrenergic receptor antagonist
L 748337 is a selective, competitive beta 3 adrenergic receptor antagonist, that binds to the receptor with an affinity of 04 nM. The affinities for beta-1 and beta-2 receptors are 154 and 204 nM, respectively. The compound potently inhibits agonist-stimulated lipolysis in adipocytes, as well as agonist induced relaxation of smooth muscle.
Features and Benefits
This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Xiaobing Wang et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 38(2), 514-530 (2016-02-02)
The role of the β3-adrenergic receptor (β3-AR) agonist BRL37344 in atrial fibrillation (AF) structural remodeling and the underlying mechanisms as a therapeutic target were investigated. Four groups of dogs were evaluated: sham, pacing, β3-AR agonist BRL37344 (β3-AGO), and β3-AR antagonist
Ziwen Wang et al.
Molecular medicine (Cambridge, Mass.), 26(1), 54-54 (2020-06-07)
Our objective was to investigate the efficacy of the beta-3 adrenergic receptor (β3-AR) agonist BRL37344 for the prevention of liver steatosis and inflammation associated with nonalcoholic fatty liver disease (NAFLD). Four groups were established: a control group (given a standard